9 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)Geographic Atrophy Secondary to Age-related Macular DegenerationRecruitingPhase 1 / Phase 22026-10-08NCT07392255
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsHemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndromeRecruitingPhase 32026-10-08NCT06499285
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibHemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, bone marrow disorder, hematologic disorder, primary myelofibrosisRecruitingPhase 32026-10-01NCT07623161
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVDMixed Dyslipidemia; Primary HypercholesterolemiaActive, not recruitingNot stated2026-09-24NCT05399992
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport SyndromeAlport syndrome, Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Abnormalities, Urogenital Diseases, connective tissue disorder, hereditary nephritis, kidney disorder, nephritis, urinary system disorderActive, not recruitingPhase 22026-09-18NCT07211685
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degenerationRecruitingPhase 32026-09-11NCT04663750
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorderRecruitingPhase 32026-09-04NCT07517263
Left Ventricular Thrombus RegistryLeft Ventricular ThrombusRecruitingNot stated2026-07-16NCT06963567
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERMeye disorder, preretinal fibrosis, retinal disorderRecruitingNot applicable2026-07-16NCT05145491